Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies

Bone Marrow Transplant. 2022 Jun;57(6):1034-1037. doi: 10.1038/s41409-022-01679-6. Epub 2022 Apr 16.

Lukas Kevlicius^{1

2}, Ruta Cepulyte³, Dominika Vasilevska⁴, Laimonas Griskevicius^{3

4}, Andrius Zucenka^{3

4}

¹ Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. lukas.kevlicius@santa.lt.
² Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. lukas.kevlicius@santa.lt.
³ Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
⁴ Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

No abstract available

Publication types